<?xml version="1.0" encoding="UTF-8"?>
<table xmlns="http://www.w3.org/1999/xhtml">
 <thead>
  <tr>
   <th>Art-id</th>
   <th>label</th>
   <th>caption</th>
  </tr>
 </thead>
 <tr>
  <td>PMC3544629</td>
  <td>
   <a href="../PMC3544629/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>International Classification of Diseases, Tenth Revision (IC ... </td>
 </tr>
 <tr>
  <td>PMC3544629</td>
  <td>
   <a href="../PMC3544629/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>International Classification of Diseases, Tenth Revision (IC ... </td>
 </tr>
 <tr>
  <td>PMC3544629</td>
  <td>
   <a href="../PMC3544629/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Pediatric hospitalizations for lower respiratory tract infec ... </td>
 </tr>
 <tr>
  <td>PMC3544629</td>
  <td>
   <a href="../PMC3544629/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Hospitalizations and average length of stay among high-risk ... </td>
 </tr>
 <tr>
  <td>PMC3544629</td>
  <td>
   <a href="../PMC3544629/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>Hospitalization rates for lower respiratory tract infection ... </td>
 </tr>
 <tr>
  <td>PMC3544629</td>
  <td>
   <a href="../PMC3544629/sections/tables/table_6.xml">Table 6</a>
  </td>
  <td>British Columbia population estimates and projections to 202 ... </td>
 </tr>
 <tr>
  <td>PMC3544629</td>
  <td>
   <a href="../PMC3544629/sections/tables/table_7.xml">Table 7</a>
  </td>
  <td>Projections for lower respiratory tract infection hospitaliz ... </td>
 </tr>
 <tr>
  <td>PMC3702433</td>
  <td>
   <a href="../PMC3702433/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Table 1 The demographic and clinical characteristics of stud ... </td>
 </tr>
 <tr>
  <td>PMC3702433</td>
  <td>
   <a href="../PMC3702433/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Incidence of CAP among adults by gender and age group, Nha T ... </td>
 </tr>
 <tr>
  <td>PMC3702433</td>
  <td>
   <a href="../PMC3702433/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>The bacterial and viral aetiology of the enrolled patients</td>
 </tr>
 <tr>
  <td>PMC3787546</td>
  <td>
   <a href="../PMC3787546/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Differences between asthma and COPD.</td>
 </tr>
 <tr>
  <td>PMC5327784</td>
  <td>
   <a href="../PMC5327784/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Some past emerging infectious disease epidemics and probable ... </td>
 </tr>
 <tr>
  <td>PMC5327784</td>
  <td>
   <a href="../PMC5327784/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Top priority emerging infectious diseases.</td>
 </tr>
 <tr>
  <td>PMC5327784</td>
  <td>
   <a href="../PMC5327784/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Major neglected tropical diseases.</td>
 </tr>
 <tr>
  <td>PMC5735522</td>
  <td>
   <a href="../PMC5735522/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Viruses utilized to assess the analytical specificity of the ... </td>
 </tr>
 <tr>
  <td>PMC5735522</td>
  <td>
   <a href="../PMC5735522/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Primer and probe sequences used in the CDC and PAHO RT-qPCR ... </td>
 </tr>
 <tr>
  <td>PMC5735522</td>
  <td>
   <a href="../PMC5735522/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Analytical sensitivity of ZIKV RT-qPCR and RT-iiPCR assays u ... </td>
 </tr>
 <tr>
  <td>PMC5735522</td>
  <td>
   <a href="../PMC5735522/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Analytical sensitivity of ZIKV RT-qPCR and RT-iiPCR assays u ... </td>
 </tr>
 <tr>
  <td>PMC5735522</td>
  <td>
   <a href="../PMC5735522/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>Inclusivity and exclusivity test panel used to compare the s ... </td>
 </tr>
 <tr>
  <td>PMC5735522</td>
  <td>
   <a href="../PMC5735522/sections/tables/table_6.xml">Table 6</a>
  </td>
  <td>Detection rates per assay according to the specimen’s viral ... </td>
 </tr>
 <tr>
  <td>PMC5735522</td>
  <td>
   <a href="../PMC5735522/sections/tables/table_7.xml">Table 7</a>
  </td>
  <td>Agreement between the RT-iiPCR and RT-qPCR assays for detect ... </td>
 </tr>
 <tr>
  <td>PMC5765694</td>
  <td>
   <a href="../PMC5765694/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Descriptive characteristics of the study samples ( n = 75)</td>
 </tr>
 <tr>
  <td>PMC5819479</td>
  <td>
   <a href="../PMC5819479/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Numbers of RNA virus species that exhibit specified levels o ... </td>
 </tr>
 <tr>
  <td>PMC5819479</td>
  <td>
   <a href="../PMC5819479/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Numbers of RNA virus species naturally infecting additional ... </td>
 </tr>
 <tr>
  <td>PMC5819479</td>
  <td>
   <a href="../PMC5819479/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Numbers of RNA virus species with specified routes of transm ... </td>
 </tr>
 <tr>
  <td>PMC6156540</td>
  <td>
   <a href="../PMC6156540/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Exemplary clinical trials employing viral vector based vacci ... </td>
 </tr>
 <tr>
  <td>PMC6156540</td>
  <td>
   <a href="../PMC6156540/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Clinical trials employing DNA vaccines in pandemic settings.</td>
 </tr>
 <tr>
  <td>PMC6156540</td>
  <td>
   <a href="../PMC6156540/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Clinical trials employing RNA vaccines in pandemic settings.</td>
 </tr>
 <tr>
  <td>PMC6156540</td>
  <td>
   <a href="../PMC6156540/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Summarized properties of discussed vaccine technologies.</td>
 </tr>
 <tr>
  <td>PMC6369834</td>
  <td>
   <a href="../PMC6369834/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Western Balkan countries participation in ECDC-supported lab ... </td>
 </tr>
 <tr>
  <td>PMC6369834</td>
  <td>
   <a href="../PMC6369834/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Western Balkan countries' capacities to confirm cases by pri ... </td>
 </tr>
 <tr>
  <td>PMC6509602</td>
  <td>
   <a href="../PMC6509602/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Responses to open-ended questions on EIDs</td>
 </tr>
 <tr>
  <td>PMC6509602</td>
  <td>
   <a href="../PMC6509602/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Key barriers and proposed solutions relating to EIDs</td>
 </tr>
 <tr>
  <td>PMC6509602</td>
  <td>
   <a href="../PMC6509602/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Responses to open-ended questions on antimicrobial resistanc ... </td>
 </tr>
 <tr>
  <td>PMC6509602</td>
  <td>
   <a href="../PMC6509602/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Key barriers and proposed solutions relating to AMR and anti ... </td>
 </tr>
 <tr>
  <td>PMC6509602</td>
  <td>
   <a href="../PMC6509602/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>Processes and activities proposed to move the National Emerg ... </td>
 </tr>
 <tr>
  <td>PMC6594388</td>
  <td>
   <a href="../PMC6594388/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Novel therapeutics currently under development (clinical tri ... </td>
 </tr>
 <tr>
  <td>PMC6727070</td>
  <td>
   <a href="../PMC6727070/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Integrated aetiology analysis input values for sensitivity a ... </td>
 </tr>
 <tr>
  <td>PMC6727070</td>
  <td>
   <a href="../PMC6727070/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Demographic and clinical characteristics of cases without HI ... </td>
 </tr>
 <tr>
  <td>PMC6727070</td>
  <td>
   <a href="../PMC6727070/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Demographic and clinical characteristics of cases with a pos ... </td>
 </tr>
 <tr>
  <td>PMC6727070</td>
  <td>
   <a href="../PMC6727070/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Organisms identified by culture and PCR of lung aspirate or ... </td>
 </tr>
 <tr>
  <td>PMC6911100</td>
  <td>
   <a href="../PMC6911100/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Middle East Respiratory Syndrome Coronavirus (MERS-CoV) occu ... </td>
 </tr>
 <tr>
  <td>PMC6925075</td>
  <td>
   <a href="../PMC6925075/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Coalition for Epidemic Preparedness Innovations investors (a ... </td>
 </tr>
 <tr>
  <td>PMC6925075</td>
  <td>
   <a href="../PMC6925075/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>The Coalition for Epidemic Preparedness Innovations (CEPI) f ... </td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Search terms.</td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Inclusion and exclusion criteria.</td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Summary results of studies reviewed including type of screen ... </td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>WHO temporary recommendations for entry and exit screening a ... </td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_6.xml">Table 6</a>
  </td>
  <td>Screening methods and accompanying measures.</td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_7.xml">Table 7</a>
  </td>
  <td>Number of travelers screened, suspected and confirmed cases ... </td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_8.xml">Table 8</a>
  </td>
  <td>Number of travelers screened, suspected and confirmed cases ... </td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_9.xml">Table 9</a>
  </td>
  <td>Reported facts about the cost of screening measure.</td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_10.xml">Table 10</a>
  </td>
  <td>Assessment of public health impact as reported by authors.</td>
 </tr>
 <tr>
  <td>PMC6926871</td>
  <td>
   <a href="../PMC6926871/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Degree of success, limitations and concomitant effects of en ... </td>
 </tr>
 <tr>
  <td>PMC6935926</td>
  <td>
   <a href="../PMC6935926/sections/tables/table_1.xml">TABLE 1</a>
  </td>
  <td>Summary of results from Nanopore sequencing based on pooled ... </td>
 </tr>
 <tr>
  <td>PMC6939334</td>
  <td>
   <a href="../PMC6939334/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>US FDA-approved monoclonal antibody on the market</td>
 </tr>
 <tr>
  <td>PMC6939334</td>
  <td>
   <a href="../PMC6939334/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Top 10 best-selling monoclonal antibody drugs in 2018</td>
 </tr>
 <tr>
  <td>PMC6939334</td>
  <td>
   <a href="../PMC6939334/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Key patents covering phage-displayed antibody libraries</td>
 </tr>
 <tr>
  <td>PMC6939334</td>
  <td>
   <a href="../PMC6939334/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>The major platforms of human antibody transgenic animals in ... </td>
 </tr>
 <tr>
  <td>PMC6939334</td>
  <td>
   <a href="../PMC6939334/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>US FDA-approved human mAbs</td>
 </tr>
 <tr>
  <td>PMC6941257</td>
  <td>
   <a href="../PMC6941257/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>A summary of aptamers selected against bacterial cells or to ... </td>
 </tr>
 <tr>
  <td>PMC6941257</td>
  <td>
   <a href="../PMC6941257/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>A summary of several aptamers developed for the treatment of ... </td>
 </tr>
 <tr>
  <td>PMC6941257</td>
  <td>
   <a href="../PMC6941257/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>A summary of several aptamers developed for the treatment of ... </td>
 </tr>
 <tr>
  <td>PMC6958603</td>
  <td>
   <a href="../PMC6958603/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Mean indicators’ scores (range 1–3) for each attribute used ... </td>
 </tr>
 <tr>
  <td>PMC6958603</td>
  <td>
   <a href="../PMC6958603/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Indicators for data quality and completeness, timeliness, re ... </td>
 </tr>
 <tr>
  <td>PMC6958603</td>
  <td>
   <a href="../PMC6958603/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Indicators for simplicity and acceptability used for the eva ... </td>
 </tr>
 <tr>
  <td>PMC6958603</td>
  <td>
   <a href="../PMC6958603/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Indicators for stability used for the evaluation of the infl ... </td>
 </tr>
 <tr>
  <td>PMC6958603</td>
  <td>
   <a href="../PMC6958603/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>Indicators for utility and sustainability used for the evalu ... </td>
 </tr>
 <tr>
  <td>PMC6961264</td>
  <td>
   <a href="../PMC6961264/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Influenza vaccine effectiveness estimates for community-dwel ... </td>
 </tr>
 <tr>
  <td>PMC6961264</td>
  <td>
   <a href="../PMC6961264/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Descriptive characteristics of community-dwelling adults age ... </td>
 </tr>
 <tr>
  <td>PMC6961264</td>
  <td>
   <a href="../PMC6961264/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Descriptive characteristics of community-dwelling adults age ... </td>
 </tr>
 <tr>
  <td>PMC6961264</td>
  <td>
   <a href="../PMC6961264/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Descriptive characteristics of community-dwelling adults age ... </td>
 </tr>
 <tr>
  <td>PMC6969405</td>
  <td>
   <a href="../PMC6969405/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Detailed pathological, histological, and bacteriological fin ... </td>
 </tr>
 <tr>
  <td>PMC6969405</td>
  <td>
   <a href="../PMC6969405/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Nidovirus detection in different snake species</td>
 </tr>
 <tr>
  <td>PMC6969405</td>
  <td>
   <a href="../PMC6969405/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Nucleotide sequence identity (%) of the two newly generated ... </td>
 </tr>
 <tr>
  <td>PMC6969405</td>
  <td>
   <a href="../PMC6969405/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Snake nidovirus RNA distribution in tissues of nine green tr ... </td>
 </tr>
 <tr>
  <td>PMC6969405</td>
  <td>
   <a href="../PMC6969405/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>Pathologic and molecular findings of selected snakes with di ... </td>
 </tr>
 <tr>
  <td>PMC6969405</td>
  <td>
   <a href="../PMC6969405/sections/tables/table_6.xml">Table 6</a>
  </td>
  <td>Symptoms of snake nidovirus RNA positive and negative animal ... </td>
 </tr>
 <tr>
  <td>PMC6981968</td>
  <td>
   <a href="../PMC6981968/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Effects of disclosure of hospital list.</td>
 </tr>
 <tr>
  <td>PMC6981968</td>
  <td>
   <a href="../PMC6981968/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Results of sensitivity analysis of the time taken to complet ... </td>
 </tr>
 <tr>
  <td>PMC7000305</td>
  <td>
   <a href="../PMC7000305/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Baseline Characteristics.</td>
 </tr>
 <tr>
  <td>PMC7000305</td>
  <td>
   <a href="../PMC7000305/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Odds Ratio for Confirmed Cases of MERS-CoV Infection.</td>
 </tr>
 <tr>
  <td>PMC7017508</td>
  <td>
   <a href="../PMC7017508/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Demographic characteristics of hospitalized children with co ... </td>
 </tr>
 <tr>
  <td>PMC7017508</td>
  <td>
   <a href="../PMC7017508/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Prevalence of causative respiratory viruses and Mycoplasma p ... </td>
 </tr>
 <tr>
  <td>PMC7017508</td>
  <td>
   <a href="../PMC7017508/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Comparison of clinical and laboratory findings according to ... </td>
 </tr>
 <tr>
  <td>PMC7019290</td>
  <td>
   <a href="../PMC7019290/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Examples of known animal viruses reported in available metag ... </td>
 </tr>
 <tr>
  <td>PMC7019290</td>
  <td>
   <a href="../PMC7019290/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Examples of novel viruses found in farm animals by available ... </td>
 </tr>
 <tr>
  <td>PMC7028525</td>
  <td>
   <a href="../PMC7028525/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Reported cases of pulmonary silicone embolism syndrome.</td>
 </tr>
 <tr>
  <td>PMC7033854</td>
  <td>
   <a href="../PMC7033854/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Comparisons of baseline characteristics at admission</td>
 </tr>
 <tr>
  <td>PMC7033854</td>
  <td>
   <a href="../PMC7033854/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Comparisons of laboratory and radiologic parameters between ... </td>
 </tr>
 <tr>
  <td>PMC7033854</td>
  <td>
   <a href="../PMC7033854/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Characteristics of fever and response to antipyretics betwee ... </td>
 </tr>
 <tr>
  <td>PMC7033854</td>
  <td>
   <a href="../PMC7033854/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Comparison of clinico-laboratory findings between Adv and No ... </td>
 </tr>
 <tr>
  <td>PMC7033854</td>
  <td>
   <a href="../PMC7033854/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>Comparison of clinico-laboratory variables between combined ... </td>
 </tr>
 <tr>
  <td>PMC7033854</td>
  <td>
   <a href="../PMC7033854/sections/tables/table_6.xml">Table 6</a>
  </td>
  <td>Comparisons of treatment outcomes between Adv and Non-Adv gr ... </td>
 </tr>
 <tr>
  <td>PMC7034298</td>
  <td>
   <a href="../PMC7034298/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>The clinical and immunological characterization.</td>
 </tr>
 <tr>
  <td>PMC7034298</td>
  <td>
   <a href="../PMC7034298/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Summary of patients with IKK2 deficiency previously reported ... </td>
 </tr>
 <tr>
  <td>PMC7041086</td>
  <td>
   <a href="../PMC7041086/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Clinical and spirometric characteristics at baseline. Descri ... </td>
 </tr>
 <tr>
  <td>PMC7041086</td>
  <td>
   <a href="../PMC7041086/sections/tables/table_2.xml">Table 2</a>
  </td>
  <td>Characteristics of the infection disease at baseline. Compar ... </td>
 </tr>
 <tr>
  <td>PMC7041086</td>
  <td>
   <a href="../PMC7041086/sections/tables/table_3.xml">Table 3</a>
  </td>
  <td>Description of microbiological findings in the Viral Infecti ... </td>
 </tr>
 <tr>
  <td>PMC7041086</td>
  <td>
   <a href="../PMC7041086/sections/tables/table_4.xml">Table 4</a>
  </td>
  <td>Outcomes (Delta-FEV-1, Acute rejection, BOS and Death) after ... </td>
 </tr>
 <tr>
  <td>PMC7041086</td>
  <td>
   <a href="../PMC7041086/sections/tables/table_5.xml">Table 5</a>
  </td>
  <td>Outcomes (BOS and AR) after 6 months of observation. Descrip ... </td>
 </tr>
 <tr>
  <td>PMC7047374</td>
  <td>
   <a href="../PMC7047374/sections/tables/table_1.xml">Table 1</a>
  </td>
  <td>Definition of those parameters in the Bats-Hosts-Reservoir-P ... </td>
 </tr>
</table>
